维亚生物(01873.HK)中期扣非净利润增长47.4%至9860万元
格隆汇8月28日丨维亚生物(01873.HK)发布中期业绩,截至2019年6月30日止6个月,公司实现收入1.423亿元人民币(下同),同比增长83.9%;毛利7189.1万元,同比增长70.0%;基本每股收益0.04元;拟派中期股息每股0.005港元。
集团现营运世界领先的基于结构的早期新药发现技术平台,以及具有高技术壁垒的系统化、科学化、模块化的孵化平台。集团已开发一种具拓展性的业务模式,将传统的服务换现金(CFS)模式(据此本集团向非投资对象的客户收取现金服务费)与独有的服务换股权(EFS)模式相结合。按EFS模式,集团向特选的客户及所投资的具备发展前景的生物科技公司提供药物发现及╱或孵化服务以换取该等客户的股权或经济利益。
于报告期内,CFS业务模式持续为集团贡献了稳定的现金流。就EFS业务模式而言,集团持续与全球顶尖科学家及极具前景的生物科技初创公司合作,并扩张了孵化企业数量。于报告期内,集团的收益由去年同期约7740万元大幅增加至约1.423亿元元,较去年同期增幅为83.9%。集团的扣非净利润由去年同期约6690万元增加至报告期约9860万元,较去年同期增幅为47.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.